Comment on Udell et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial. Diabetes Care 2015;38:696-705

Affiliations

¹ Bharti Hospital, Karnal, Haryana, India.
² Department of Medicine, Government Medical College & Hospital, Sector 32, Chandigarh, India yash_deep_gupta@yahoo.co.in.
³ Excel Hospitals, Guwahati, Assam, India.
⁴ Department of Neurology, Postgraduate Institute of Medical Education & Research, Chandigarh, India.

Comment

Sanjay Kalra et al. Diabetes Care. 2015 Jun.

. 2015 Jun;38(6):e88-9.

doi: 10.2337/dc15-0006.

¹ Bharti Hospital, Karnal, Haryana, India.
² Department of Medicine, Government Medical College & Hospital, Sector 32, Chandigarh, India yash_deep_gupta@yahoo.co.in.
³ Excel Hospitals, Guwahati, Assam, India.
⁴ Department of Neurology, Postgraduate Institute of Medical Education & Research, Chandigarh, India.

No abstract available

Comment on

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial.
Udell JA, Bhatt DL, Braunwald E, Cavender MA, Mosenzon O, Steg PG, Davidson JA, Nicolau JC, Corbalan R, Hirshberg B, Frederich R, Im K, Umez-Eronini AA, He P, McGuire DK, Leiter LA, Raz I, Scirica BM; SAVOR-TIMI 53 Steering Committee and Investigators. Udell JA, et al. Diabetes Care. 2015 Apr;38(4):696-705. doi: 10.2337/dc14-1850. Epub 2014 Dec 31. Diabetes Care. 2015. PMID: 25552421 Clinical Trial.